MétaCan
Menu
Back to cohort
Record W2793325090 · doi:10.3899/jrheum.180062

Successful Trial Design and Planning in Systemic Sclerosis: Does It Take a Village?

2018· letter· en· W2793325090 on OpenAlexvenueno aff
Lesley Ann Saketkoo

Bibliographic record

VenueThe Journal of Rheumatology · 2018
Typeletter
Languageen
FieldMedicine
TopicSystemic Sclerosis and Related Diseases
Canadian institutionsnot available
Fundersnot available
KeywordsMedicinePlaceboDiscontinuationResearch designScrutinyAdverse effectClinical trialRandomized controlled trialHarmIntensive care medicineClinical study designDiseaseAlternative medicinePhysical therapyInternal medicineFamily medicinePathology

Abstract

fetched live from OpenAlex

Negative trial reporting, especially in rare diseases, provides essential information. The design and analysis of a “negative” trial, in diseases for which few potential treatments and no cure exist, warrants particular scrutiny to determine whether the trial was truly negative, or rather a “failed” trial owing to other design, financial, planning, or recruitment impediments1. A trial that is discontinued early warrants the label negative if an unbiased, independent data safety monitoring board identified either a harm signal (excessive intolerance or drug-related adverse events) or a clear worsening of the disease state in comparison to placebo. In an article by Hsu, et al , in this issue of The Journal , the authors describe a 52-week randomized double-blind placebo-controlled multicenter phase II study of pomalidomide2. The sponsors have conceded to the reviewers that the study was discontinued early because of poor recruitment. Yet the article’s discussion section persists in stating that discontinuation by the sponsor was due to lack of drug efficacy. To be clear, there exists no statistical application capable of calculating a reliable result in any of the study variables between the 4 treatment and the 7 placebo cases completing a study that was powered for a sample of 88. Thus, the study results carry similar statistical weight to the initial anecdotal case reports of perceived efficacy of pomalidomide by systemic sclerosis (SSc) specialists — cases that likely inspired moving the drug to trial. SSc disease behavior remains complex and challenging to the most seasoned SSc clinician researchers who are well-acclimated to a cautious approach to data interpretation in this “rare” and exceptionally complex disease. In a journal less cognizant of the humbling landscape in SSc clinical trial design, this study would have slipped by as a negative study, generating an inaccurate interpretation of the … Address correspondence to Dr. L.A. Saketkoo, MD, MPH, Associate Professor of Medicine, Tulane University School of Medicine, Division of Pulmonary Medicine and Critical Care, 1430 Tulane Ave., New Orleans, Louisiana 70112, USA. E-mail: lsaketk{at}tulane.edu

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.608
metaresearch head score (Gemma)0.754
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.608
Threshold uncertainty score0.483

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.6080.754
Meta-epidemiology (narrow)0.0030.003
Meta-epidemiology (broad)0.0090.006
Bibliometrics0.0050.005
Science and technology studies0.0100.036
Scholarly communication0.0300.038
Open science0.0130.013
Research integrity0.0430.056
Insufficient payload (model declined to judge)0.0080.007

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.041
GPT teacher head0.275
Teacher spread0.234 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations2
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of RheumatologySame topicSystemic Sclerosis and Related DiseasesFrench-language works237,207